Altium Capital Management LLC purchased a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,424,400 shares of the company's stock, valued at approximately $5,384,000. COMPASS Pathways accounts for about 1.5% of Altium Capital Management LLC's portfolio, making the stock its 24th largest holding. Altium Capital Management LLC owned 2.08% of COMPASS Pathways as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of CMPS. Affinity Asset Advisors LLC boosted its holdings in COMPASS Pathways by 183.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company's stock valued at $3,215,000 after purchasing an additional 550,000 shares during the last quarter. Barclays PLC lifted its holdings in COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after acquiring an additional 8,718 shares during the last quarter. Marshall Wace LLP purchased a new position in COMPASS Pathways in the fourth quarter worth approximately $1,395,000. Franklin Resources Inc. increased its stake in COMPASS Pathways by 4.4% during the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company's stock worth $1,810,000 after acquiring an additional 12,599 shares during the last quarter. Finally, Brown University raised its position in COMPASS Pathways by 194.6% in the fourth quarter. Brown University now owns 214,200 shares of the company's stock valued at $810,000 after purchasing an additional 141,500 shares during the period. Institutional investors and hedge funds own 46.19% of the company's stock.
COMPASS Pathways Stock Up 5.0 %
NASDAQ:CMPS traded up $0.18 during midday trading on Wednesday, reaching $3.75. The company had a trading volume of 1,416,316 shares, compared to its average volume of 783,774. COMPASS Pathways plc has a 12-month low of $2.49 and a 12-month high of $9.63. The firm has a market capitalization of $347.52 million, a price-to-earnings ratio of -1.70 and a beta of 2.34. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock's fifty day simple moving average is $3.39 and its 200-day simple moving average is $4.23.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, sell-side analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. Royal Bank of Canada reissued an "outperform" rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Cantor Fitzgerald restated an "overweight" rating on shares of COMPASS Pathways in a report on Friday, March 28th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research report on Thursday, February 27th. They issued a "buy" rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group decreased their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $20.20.
Get Our Latest Research Report on COMPASS Pathways
COMPASS Pathways Company Profile
(
Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Further Reading
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
